Article

Hypertension and Diabetes Mellitus

Abstract

Citation:European Cardiovascular Disease 2006;2(1):21–4

Open access:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

There has been an increase in the prevalence of diabetes mellitus over the past 40 years, both in the US and worldwide. The worldwide prevalence of diabetes in 2000 was approximately 2.8% and is estimated to grow to 4.4% by 2030. This translates to a projected rise of diabetes from 171 million in 2000 to well over 350 million in 2030. The epidemic of diabetes will continue to rise as there is growing prevalence of obesity in children, which predisposes to diabetes. There is considerable evidence for an increased prevalence of hypertension in diabetic persons. In a large prospective cohort study that included 12,550 adults, the development of type 2 diabetes was almost 2.5 times as likely in persons with hypertension than in their normotensive counterparts. Similarly, evidence points to increased prevalence of hypertension in diabetic persons.

Moreover, each pathophysiological disease entity serves to exacerbate the other. Both hypertension and diabetes predisposes to the development of cardiovascular disease (CVD) and renal disease. Subjects with diabetes are at about 60% increased risk of early mortality. The age-adjusted relative risk of death due to cardiovascular events in persons with type 2 diabetes is three-fold higher than in the general population. The presence of hypertension in diabetic patients substantially increases the risks of coronary heart disease, stroke, nephropathy and retinopathy. Indeed, when hypertension coexists with diabetes, the risk of CVD is increased by 75%, which further contributes to the overall morbidity and mortality of an already high-risk population. Generally, hypertension in type 2 diabetic persons clusters with other CVD risk factors such as microalbuminuria, central obesity, insulin resistance, dyslipidaemia, hypercoagulation, increased inflammation and left ventricular hypertrophy. This clustering risk factor in diabetic patients ultimately results in the development of CVD, which is the major cause of premature mortality in patients with type 2 diabetes.

Pathophysiology of Hypertension in the Diabetic Patient

Epidemiologic studies provide evidence for co-existence of hypertension and diabetes and possibly point towards a common genetic and environmental factor promoting both diabetes and hypertension. Similarly, clustering of hypertension, insulin resistance or frank type 2 diabetes, hyperlipidaemia and central obesity have been documented in several populations. Insulin resistance, increased tissue inflammation and reactive oxygen species (ROS) production resulting in endothelial dysfunction, increased tissue renin-angiotensin-aldosterone system (RAAS) and increased sympathetic nervous system (SNS) activity have all been implicated in this complex pathophysiology of diabetes and hypertension.

Diabetes, Insulin Resistance and Hypertension - A Complex Interrelated Process and the Crucial Role of RAAS

It is estimated that about 25-47% of persons with hypertension have insulin resistance or impaired glucose tolerance. With insulin resistance there are impaired biological and physiological tissue responses to insulin. The relationship of insulin resistance, diabetes and hypertension is complex and interrelated. Untreated patients with essential hypertension have higher fasting and postprandial insulin levels than age- and sex-matched normotensive persons, regardless of body mass; a direct correlation between plasma insulin levels and blood pressure (BP) exists. Interestingly, the relationship between hyperinsulinaemia and hypertension is not seen in secondary hypertension. This indicates that insulin resistance and hyperinsulinaemia are not consequences of hypertension, but rather a genetic predisposition that acts as a fertile soil for both diseases. This notion is supported by the observation that there is abnormal glucose metabolism in the offspring of hypertensive parents. Thus, there is a strong association between hypertension, diabetes and insulin resistance.

There is also a strong association between upregulation of RAAS, hypertension and diabetes. This upregulation of RAAS results in enhanced generation of ROS and may explain impaired glucose utilisation as well as hypertension associated with insulin resistance and type 2 diabetes. It has been proposed that increased autocrine/paracrine activity of angiotensin II (ANG II) results in diminished action of insulin and insulin growth factor-1 (IGF-1) signalling through the PI3K/Akt pathway, resulting in inhibition of mechanisms involved in the vasodilator and glucose transport properties of insulin and IGF-1 (see Figure 1 and 2). Insulin activates the PI3K/Akt system in skeletal muscle, adipose, and myocardial tissues and initiates translocation of the GLUT4 glucose receptor to the cell membrane. The unregulated ANG II acts through its receptor (AT1R) and results in formation of ROS and the activation of low-molecular- weight G proteins such as Rho A. Activation of these small G proteins and consequent enhancement of the generation of ROS inhibits insulin/IGF-1 actions mediated through PI3K/Akt signalling including activation of endothelial nitric oxide (NO) synthase (eNOS) activity, Na+ pump activation, and Ca2+-myosin light chain (MLC) desensitisation.

Similar RAAS-mediated increases in oxidative stress are likely contribute to insulin resistance in skeletal muscles. This is supported by findings that ROS are increased in skeletal muscle from Ren-2 rats that over-express tissue ANG II, and that this effect is abolished when the animals are treated with an AT1R blocker. This and numerous other studies have shown that therapy with angiotensin-converting enzyme inhibitors (ACE-I) decreases the progression to type 2 diabetes in high-risk patients. These and other studies imply the critical role played by RAAS and usefulness of ACE-I in the treatment of diabetes and hypertension.

Activation of the RAAS also results in increased aldosterone secretion from the adrenal gland and resultant salt retention and volume expansion and consequent hypertension. Further, aldosterone also contributes to hypertension by enhancing SNS activ-ity, decreasing parasympathetic activity, and reducing baroreceptor sensitivity. Other effects of aldosterone in kidney, besides the salt retension, include increased extracellular matrix deposition by glomerular cells, leading to glomerulosclerosis and hypertension.

Blockade of the aldosterone receptor in the Randomized Aldactone Evaluation Study (RALES) using spironolactone in patients with chronic moderate to severe heart failure, corresponding to New York Heart Association (NYHA) class 3 and 4, reduced mortality by 30%. More recently, the selective aldosterone receptor antagonist eplerenone in heart failure patients showed a similar decrease in mortality with fewer side effects.

Other possible causes of hypertension with diabetes and insulin resistance/hyperinsulinaemia include activation of the sympathetic nervous system, increased renal tubular sodium retention, elevated intracellular calcium concentration and vascular smooth muscle cell proliferation and atherosclerosis, and impaired NO metabolism in skeletal muscle. Another mechanism is the upregulation of vascular AT1Rs by post-transcriptional mechanisms enhancing the vaso-constrictive and volume-expanding actions of the RAAS. Some studies even suggest that excess levels of insulin can interfere with compliance of the great vessels and decrease the ability of the aorta to reflect aortic waves. Therapy targeted at insulin resistance, such as aerobic exercise or thiazolidenedione drugs, results in a decrease in BP.

Management

In patients with diabetes, the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) recommends a target BP of <130/80mmHg in order to prevent death and disability associated with high BP. Once hypertension is detected both pharmacological and non-pharmacological interventions should be implemented. Instituting lifestyle modifications is paramount, along with medical therapy at the earliest detection of the pre-hypertensive patient.

Lifestyle Changes

The first objective in any hypertensive diabetic should be to initiate lifestyle changes. These changes should include an improved diet, regular physical activity, weight management and cessation of smoking. Weight loss has shown to be an effective therapy in hypertension management. Moreover, studies have shown that modest weight loss can lower or even eliminate the need for antihypertensive medication.

Patients should be advised to adopt the Dietary Approach to Stop Hypertension (DASH) eating plan, consisting of a low sodium, high potassium, low calorie (800-1,500 kcal/day) and high fibre diet, as it is shown to be effective in lowering BP. Coupled with diet, increased physical activity, such as walking for 30-45 minutes three to five days a week, has been shown to improve lipid profiles, BP and insulin resistance.

Pharmacotherapy

The JNC 7 recommendations are consistent with guidelines from the American Diabetes Association (ADA), which has also recommended that BP in diabetics be controlled to levels of 130/80mmHg or lower. Whatever the goal level, rigorous control of BP is paramount for reducing CVD mortality and morbidity. To achieve goal BP in diabetics, two or more drugs are usually required. There is convincing evidence regarding a certain class of drugs that seems to offer certain beneficial effects over others in hypertensive diabetics.

ACE-I

There is significant evidence that interruption of the RAAS can provide cardio-protective properties. Data from several large studies, such as the Captopril Prevention Project (CAPPP) and the Micro-HOPE, a sub-study of the Heart Outcomes Prevention Evaluation (HOPE) trial, have have demonstrated the cardiovascular benefits of ACE-I. ACE-I are also known to improve insulin sensitivity, retard the progression of diabetes and even prevent the development of diabetes in hypertensive patients by inhibiting RAAS. Most notably, ACE-I have also demonstrated the ability to slow progression of nephropathy in microalbuminuric, normotensive type 2 diabetes compared with other antihypertensives.

After initiation of therapy with ACE-I or angiotensin receptor blockers (ARBs), monitoring of renal function and potassium is imperative.

ARBs

Other medications receiving considerable attention in recent years are the ARBs. The antihypertensive action of ARBs is roughly equivalent to ACE-I, but does have an improved side effect profile when compared with ACE-I. Similar to ACE-I, ARBs have beneficial effects in reducing the progression of diabetes and carry other cardiovascular and renal benefits noticed in ACE-I, by virtue of its RAAS blockade.

Several clinical trials demonstrate that ARBs also have beneficial effects on glucose metabolism that are likely independent of bradykinin-mediated mechanisms. In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, losartan reduced the relative risk of developing type 2 diabetes by 25% when compared with the beta-blocker atenolol. Similarly, reduction in the relative risk of developing diabetes was noted in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) studies.

The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial demonstrated the advantage of an ARB, valsartan, over a calcium channel blocker (CCB), amlodipine, in reducing the relative risk of new onset diabetes by 23% in patients with hypertension aged 50 years or older.

The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) is another double-blind multicentre study set up to investigate the role of an ARB and an ACE-I, alone or in combination, in the prevention the incidence of type 2 diabetes as a secondary end-point.